Delivery Order SPE2DB24D2208-SPE2DB25FHJDZ
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Humira (cf) Pen 40 mg/0.4 mls, a pharmaceutical product used primarily for the treatment of inflammatory conditions. This firm fixed price delivery order, valued at $1,510.60, represents a non-set-aside competitive award with an ultimate completion date of August 13, 2025. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of HUMIRA(CF) Pen 40 mg/0.4 mls, a pharmaceutical product used for treating autoimmune conditions. This firm fixed-price delivery order, valued at $1,132.95, represents a non-set-aside competitive award with an ultimate completion date of September 4, 2025. The product will be delivered to the contractor's facility in Conshohocken, Pennsylvania, where AmerisourceBergen...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of HUMIRA(CF) Pen 80 mg/0.8 mls, a pharmaceutical product used in the treatment of autoimmune conditions. This firm fixed price delivery order, valued at $1,453.31, represents a single transaction under AmerisourceBergen's broader pharmaceutical supply relationship with the federal government. The award was made through open competition with no set-aside designation,...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,108.54 to AmerisourceBergen Drug Corp for the supply of Humira Pen 40 mg/0.8 mL on August 13, 2025, with an ultimate completion date of August 14, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a continuation of the company's role as a critical...
- The Defense Logistics Agency awarded a delivery order valued at $14,388.29 to AmerisourceBergen Drug Corp for HUMIRA(CF) Pen 40 mg/0.4 mL on August 5, 2025, with an ultimate completion date of August 6, 2025. This firm fixed-price delivery order represents a non-competitive procurement using the company's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), which is valued at $999,999,999.00 and extends through December 2026. The pharmaceutical product will be...
- The Defense Logistics Agency awarded a $1,888.25 delivery order contract to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mls, with an ultimate completion date of August 5, 2025. This firm fixed price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves...
- The Defense Logistics Agency awarded a $5,506.33 delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mL, a pharmaceutical product used in the treatment of autoimmune conditions. This firm fixed-price contract, which is set to be completed by August 21, 2025, represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The delivery will be performed at the contractor's corporate...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mL with a ceiling value of $1,185.69. This is a firm fixed price delivery order under a non-set-aside competitive procurement. The contract is set to be completed by August 26, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's...
- The Defense Logistics Agency awarded a $5,303.20 firm fixed-price delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mls, a pharmaceutical product used in the treatment of autoimmune conditions. This non-set-aside competitive award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,265.90 to AmerisourceBergen Drug Corp for the supply of HUMIRA (CF) Pen 40 mg/0.4 mls, a pharmaceutical product used in the treatment of autoimmune conditions. This firm fixed-price, non-competitive delivery order was awarded on August 4, 2025, with an ultimate completion date of August 5, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a continuation of...
- SPE2DB24D2208Indefinite Delivery Contract
- SPE2DB24D2208-SPE2DB25FHJDZDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on September 4, 2025, for the supply of HUMIRA Pen 40 mg/0.8 mL, a pharmaceutical product used in treating autoimmune conditions. This competitively awarded, firm fixed-price delivery order carries a ceiling value of $1,156.39 and is scheduled for completion by September 5, 2025. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.99 million through December 2026, which serves as the primary vehicle for pharmaceutical procurement supporting military healthcare programs globally. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, fulfills this order from its corporate office location in the same city. As a critical federal medical procurement vendor, the company supplies a comprehensive range of pharmaceuticals and medical supplies to support Defense Health Agency operations, the U.S. Coast Guard, and other government healthcare systems. This delivery order exemplifies the company's ongoing role in the DLA's pharmaceutical supply chain, providing specialized brand-name medications essential to military medical readiness and veteran healthcare services.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.2k | 9/4/25 |